期刊
ORAL ONCOLOGY
卷 39, 期 4, 页码 397-401出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S1368-8375(02)00144-6
关键词
amifostine; oral candidiasis; radiotherapy; xerostomia
This controlled study assessed the incidence of oral candidiasis, a xerostomia-related complication, in head and neck cancer patients receiving radiotherapy, with amifostine cytoprotection. Thirty-eight patients received 500 mg arnifostine i.v., prior to each radiotherapy fraction, while 16 patients received radiotherapy alone. Oral candidiasis was diagnosed according to the criteria described before. Subjective xerostomia scales were completed by all patients. Mucositis was evaluated using the RTOG criteria. Oral candidiasis was diagnosed in 11/38 arnifostine patients and in 9/16 controls (P=0.07). Severe xerostomia was reported by 4/38 arnifostine patients and by 7/16 controls. Oral candidiasis was reduced with amifostine cytoprotection. Oral candidiasis is suggested as an objective, early, though indirect, endpoint for amifostine's radioprotective effect on salivary glands. (C) 2003 Elsevier Science Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据